Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus
Autor(es): Tiwari Mugdha, Parida Manmohan, Santhosh S R, Khan Mohsin, Dash Paban Kumar, Rao P V Lakshmana
Resumo: The recent resurgence of Chikungunya virus (CHIKV) in India - Indian Ocean Isl-s with unusual clinical severity is a matter of great public health concern. Despite the fact that CHIKV resurgence is associated with epidemic of unprecedented magnitude, no approved licensed vaccine is currently available. In the present study, a Vero cell adapted purified formalin inactivated prototype vaccine c-idate was prepared using a current Indian strain implicated with the explosive epidemic during 2006. The bulk preparation of the vaccine c-idate was undertaken in microcarrier based spinner culture using cytodex-1 in virus production serum free medium. The inactivation of the virus was accomplished through st-ard formalin inactivation protocol. The mice were immunized subcutaneously with alhydrogel gel formulation of inactivated virus preparation. The assessment of both humoral - cell-mediated immune response was accomplished through ELISA, plaque reduction neutralization test (PRNT), microcytotoxicity assay - cytokine production assay. The results revealed that formalin inactivated vaccine c-idate induced both high titered ELISA (1:51,200) - plaque reduction neutralizing antibodies (1:6400) with peak antibody titer being observed during 6 -- 8 weeks of post-vaccination. In the absence of suitable murine challenge model, the protective efficacy was established by both in vitro - in vivo neutralization tests. Further assessment of cellular immunity through in vitro stimulation of spleenocytes from immunized mice revealed augmentation of high levels of both pro- - anti-inflammatory cytokines, indicating a mixed balance of Th1 - Th2 response. These findings suggest that the formalin inactivated Chikungunya vaccine c-idate reported in this study has very good immunogenic potential to neutralize the virus infectivity by augmenting both humoral - cell-mediated immune response.
Palavras-Chave: Chikungunya; Inactivated vaccine; Humoral and CMI response; Spinner culture; Serum free medium
Imprenta: Vaccine, v. 27, n. 18, p. 2513-2522, 2009
Identificador do objeto digital: 10.1016/j.vaccine.2009.02.062
Descritores: Chikungunya virus - Biosynthesis ; Chikungunya virus - Cell ; Chikungunya virus - Immune response ; Chikungunya virus - Pathogenesis ; Chikungunya virus - Proteins ; Chikungunya virus - Antibodies ; Chikungunya virus - Cytokines ; Chikungunya virus - Immune response ; Chikungunya virus - Serology ; Chikungunya virus - T lymphocytes ; Chikungunya virus - Serology ; Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Epidemic ; Chikungunya virus - Immunology ; Chikungunya virus - Public health
Data de publicação: 2009
